The Efficiency of GnRH Antagonist (Cetrotide) in Comparison of Cabergoline in the Prevention and Treatment of Ovarian Hyperstimulation Syndrome

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Resident, Department of Obstetrics and Gynecology, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic disease that is related to ovarian stimulation by assisted reproduction technology and other infertility treatments. The aim of this study was to determine the effect of GnRH antagonist and cabergoline (Dostinx) on the treatment of ovarian hyperstimulation syndrome in women exposed to this syndrome.Methods: In this quasi-experimental study conducted in Shahid Beheshti hospital in Isfahan, Iran, in 2020, 30 infertile women treated with in vitro fertilization (IVF) were randomly divided into two groups; the first group was treated with steroids and the second group with cabergoline. Age, body mass index, total dose of prescribed gonadotropin, number of oocytes and estradiol level, length of hospital stay, and severity of ovarian hyperstimulation symptoms were determined and compared between the group.Results: The frequency of ovarian hyperstimulation syndrome in each group was 2 cases (13.33%). Besides, the amount of injected gonadotropin, number of eggs removed, estradiol level, length of hospital stay and paracentesis were not significantly different between the two groups (P > 0.050 for all).Conclusion: According to the results of the present study, the effect of cabergoline and cetrotide in preventing the occurrence and severity of ovarian hyperstimulation syndrome, length of hospital staying, and the need for paracentesis are similar, and there is no preference in using any of these drugs.

Keywords

References

  1. Namavar JB, Parsanezhad ME MD, Shomali Z, Bakhshai P, Alborzi M, Moin Vaziri NM, et al. Ovarian hyperstimulation syndrome: A narrative review of its pathophysiology, risk factors, prevention, classification, and management. Iran J Med Sci 2018; 43(3): 248-60.
  2. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73(5): 901-7.
  3. Alper MM, Smith LP, Sills ES. Ovarian hyperstimulation syndrome: Current views on pathophysiology, risk factors, prevention, and management. J Exp Clin Assist Reprod 2009; 6: 3.
  4. Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): The need for individualized not standardized treatment. Reprod Biol Endocrinol 2012; 10: 32.
  5. Holesh JE, Bass AN, Lord M. Physiology, ovulation. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2020.
  6. Raju GA, Chavan R, Deenadayal M, Gunasheela D, Gutgutia R, Haripriya G, et al. Luteinizing hormone and follicle stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation. J Hum Reprod Sci 2013; 6(4): 227-34.
  7. Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 2000; 74(3): 429-38.
  8. Kumar P, Sait SF, Sharma A, Kumar M. Ovarian hyperstimulation syndrome. J Hum Reprod Sci 2011; 4(2): 70-5.
  9. Cabar FR. Ovarian hyperstimulation syndrome in a spontaneous singleton pregnancy. Einstein (Sao Paulo) 2016; 14(2): 231-4.
  10. Ocal P, Sahmay S, Cetin M, Irez T, Guralp O, Cepni I. Serum anti-Mullerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet 2011; 28(12): 1197-203.
  11. Chen Y, Ye B, Yang X, Zheng J, Lin J, Zhao J. Predicting the outcome of different protocols of in vitro fertilization with anti-Muullerian hormone levels in patients with polycystic ovary syndrome. J Int Med Res 2017; 45(3): 1138-47.
  12. Guo JL, Zhang DD, Zhao Y, Zhang D, Zhang XM, Zhou CQ, et al. Pharmacologic interventions in preventing ovarian hyperstimulation syndrome: A systematic review and network meta-analysis. Sci Rep 2016; 6: 19093.
  13. El TO, Kopeika J, El-Toukhy T. An update on the prevention of ovarian hyperstimulation syndrome. Womens Health (Lond) 2016; 12(5): 496-503.
  14. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum Reprod Update 2002; 8(6): 559-77.
  15. Chappell N, Gibbons WE. The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome. Clin Exp Reprod Med 2017; 44(2): 57-62.
  16. Hosseini MA, Aleyasin A, Mahdavi A, Nezami R, Safdarian L, Fallahi P. The effectiveness of cabergoline for the prevention of ovarian hyperstimulation syndrome. Iran J Med Sci 2011; 36(3): 207-12.
  17. Movahedi S, Safdarian L, Agahoseini M, Aleyasin A, Khodaverdi S, Asadollah S, et al. Outcomes of assisted reproduction treatment after dopamine agonist -cabergoline- for prevention of ovarian hyper stimulation syndrome. Med J Islam Repub Iran 2016; 30: 371.
  18. Alyasin A, Mehdinejadiani S, Ghasemi M. GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article. Int J Reprod Biomed 2016; 14(9): 557-66.
  19. Lin YH, Huang MZ, Hwang JL, Chen HJ, Hsieh BC, Huang LW, et al. Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study. J Assist Reprod Genet 2013; 30(6): 753-9.
  20. Fatemi HM, Kyrou D, Papanikolaou EG, Al Buarki H, Garcia Velasco J. Letrozole and cabergoline co-administration in the early luteal phase for prevention of OHSS in a high risk patient undergoing ovarian stimulation for IVF. J Fert in Vitro 2012; 2(4): 111.
  21. Alvarez C, Alonso-Muriel I, Garcia G, Crespo J, Bellver J, Simon C, et al. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: A pilot study. Hum Reprod 2007; 22(12): 3210-4.
  22. Dehghani Firouzabadi R, Aflatoonian A, Davar R, Sekhavat L, Mansouri Moghadam F. Comparison of low-dose HCG plus GnRH agonist with standard dose of HCG alone in intrauterine insemination Cycles with antagonist protocols. Iran J Obstet Gynecol Infertil 2013; 16(46): 1-6. [In Persian].
  23. Humaidan P, Ejdrup BH, Westergaard LG, Yding AC. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: A prospective, randomized, controlled study. Fertil Steril 2010; 93(3): 847-54.
  24. Bodri D, Guillen JJ, Galindo A, Mataro D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: Findings of a large retrospective cohort study. Fertil Steril 2009; 91(2): 365-71.
Journal of Isfahan Medical School
Volume 38, Issue 606 - Serial Number 606
November and December 2021
Pages 982-988

Files

History

  • Receive Date: 03 October 2020
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics